Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB Center for Inflammation Research, Ghent, Belgium.
Department of Biomedical Molecular Biology, Faculty of Sciences, Ghent University, Ghent, Belgium.
Clin Sci (Lond). 2022 Aug 12;136(15):1111-1115. doi: 10.1042/CS20220258.
Non-alcoholic steatohepatitis (NASH) and associated end-stage liver disease is a growing cause of concern throughout the Western world. It constitutes a significant clinical burden for which therapeutic approaches are very limited. Over the last years, considerable attention has therefore been paid to identifying potential therapeutic strategies to reduce this burden. Annexin A1 (AnxA1), a calcium-phospholipid binding protein, has been proposed to be a negative regulator of inflammation in the context of NASH. In a recent publication, Gadipudi, Ramavath, Provera et al. investigated the therapeutic potential of Annexin A1 treatment in preventing the progression of NASH. They demonstrate that treatment of mice with NASH with recombinant human AnxA1 can reduce inflammation and fibrosis without affecting steatosis or metabolic syndrome. This was proposed to be achieved through the modulation of the macrophage populations present in the liver. Here, we discuss the main findings of this work and raise some outstanding questions regarding the possible mechanisms involved and the functions of distinct macrophage populations in NASH.
非酒精性脂肪性肝炎（NASH）和相关的终末期肝病是整个西方世界日益关注的问题。它给治疗带来了非常大的挑战，目前治疗方法非常有限。因此，近年来，人们非常关注寻找潜在的治疗策略来减轻这种负担。钙磷脂结合蛋白 Annexin A1（AnxA1）被认为是 NASH 中炎症的负调节剂。在最近的一篇论文中，Gadipudi、Ramavath、Provera 等人研究了 Annexin A1 治疗在预防 NASH 进展方面的治疗潜力。他们证明，用重组人 AnxA1 治疗 NASH 小鼠可以减少炎症和纤维化，而不会影响脂肪变性或代谢综合征。这是通过调节肝脏中存在的巨噬细胞群来实现的。在这里，我们讨论了这项工作的主要发现，并提出了一些关于可能涉及的机制以及 NASH 中不同巨噬细胞群的功能的悬而未决的问题。
